HONG KONG – China's Bio-Thera Solutions Ltd. has launched the phase I trial of BAT-4306F, an antibody-dependent cellular cytotoxicity (ADCC)-enhanced monoclonal antibody (MAb) that seeks to treat relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma patients.
